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Abstract: I n t r o d u c t i o n: Clostridium diffi  cile (C. diffi  cile) is a Gram-positive, anaerobic rod-shaped 
bacteria, widely spread in the human environment. In the  last decade, the  frequency and severity of 
Clostridium diffi  cile infection (CDI) have been increasing, making this particular disease one of the most 
signifi cant nosocomial infections. Th e aim of our study was an analysis of CDI risk factors, its course 
and consequences.
M a t e r i a l s  a n d  M e t h o d s: Medical documentation of the patients treated for CDI in the University 
Hospital in Cracow and St Anne’s Hospital in Miechów has been analysed. Th e  analysis focused on 
epidemiological data, blood parameters, comorbidities, recurrence rate, and complication rate (deaths 
included). As part of risk factors analysis, antibiotic use or hospitalisation in a  period of 3 months 
before the episode of infection was considered relevant. Blood tests have been performed using routinely 
employed, standard methods. 
R e s u l t s: We evaluated data of 168 people infected with C. diffi  cile, out of which there were 102 women 
(61%) and 66 men (39%). Th e median age of the patients was 74 years for the entire population with 
76  years for women and 71 years for male patients. One hundred thirteen people (67%) had been 
previously hospitalised, and 5 person was a pensioner of a nursing home. 99 people (59%) were treated 
with antibiotics within 3 months before the fi rst episode of infection. An average length of the hospital 
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stay because of CDI was 11 days. One hundred thirty persons (77%) experienced only 1 episode whereas 
38 people (23%) had more than 1 episode of infection. Th e person with the largest number of recurrences 
had 9 of them.
C o n c l u s i o n s: Th e development of CDI is an increasing problem in a group of hospitalised persons, 
particularly of an old age. Th e general use of beta-lactam antibiotics is the cause of a  larger number 
of infections with C. diffi  cile. Vast majority of patients have had at least one typical risk factor of CDI 
development.
Key words: antibiotic related diarrhoea, Clostridium diffi  cile, comorbidities, death, risk factors.
Introduction
Clostridium diffi  cile (C. diffi  cile) is a  Gram-positive, anaerobic, spore-forming 
bacillus. It was fi rst isolated in 1935 by Hall and O’Toole from meconium of 
a healthy neonate and named Bacillus diffi  cilis [1]. Th e  importance of this bacterium 
in pathogenesis of diseases of the  large intestine in humans increased with 
the  introduction of antibiotics. In 1974 Tedesco et al. reported diarrhoea in 21% 
of patients treated with clindamycin and found pseudomembranes in endoscopy 
in half of those subjects [2]. Th e  syndrome resulting from C. diffi  cile infection and 
presence of its toxins in large intestine was named Clostridium diffi  cile infection 
(CDI). In recent decade prevalence of CDI has increased, as has the  incidence of 
severe course of the disease. Th e  increasing severity of infections was associated with 
the  emergence of a  new, fl uoroqinolone-resistant, hypervirulent BI/NAP1/027 strain 
(North American pulsed-fi eld type 1, polymerase chain reaction ribotype 027). Th is 
strain produces multiple-fold amounts of toxin A  and toxin B, as well as a  binary 
toxin. BI/NAP1/027 strain has been fi rst isolated in North America, then in many 
countries in Europe, including Poland, and in the  following years on nearly every 
continent [3–9].
The aim of our study was an analysis of CDI risk factors, its course and 
consequences.
Materials and Methods
Data analysis
In our retrospective study medical documentation of the  patients treated from 
January 2011 till December 2013 for CDI in the  Department of Infectious Diseases 
of University Hospital in Cracow (n = 108) and treated from January 2013 till 
December 2013 in St Anne’s Hospital in Miechow (n = 60) has been analysed. An 
episode of CDI was defi ned according European Society of Clinical Microbiology 
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and Infectious Diseases (ESCMID) guidelines as a  clinical picture compatible with 
CDI and microbiological evidence of free toxins and the  presence of C. diffi  cile in 
stool without reasonable evidence of another cause of diarrhoea [3]. Recurrence was 
defi ned when CDI re-occured within 8 weeks aft er the  onset of a  previous episode, 
provided the  symptoms from the  previous episode resolved aft er completion of 
initial treatment [3]. Diarrhoea was defi ned as passage of 3 or more unformed 
stools in 24  hours. The  infection was confirmed by detection of C. difficile 
toxins in faeces using the  TOX A/B Quick Check Complete test kit (WAMPOL, 
TechLab, USA). 
Th e analysis focused on epidemiological data, blood parameters, comorbidities, 
recurrence rate, and complication rate (deaths included). As part of risk factors 
analysis, antibiotic use or hospitalisation in a period of 3 months before the episode 
of infection was considered relevant. Blood tests have been performed using routinely 
employed, standard methods. 
Statistics
Elements of descriptive statistics have been used in the  analysis — all data are 
presented as means or medians and lower (Q25), upper (Q75) quartiles. Normal 
distribution of variables was checked using the  Shapiro-Wilk test. Diff erences 
between groups of patients who survived and who died were determined using or 
the Mann-Whitney U-test if normality was not observed. Calculations were performed 
using Statistica 13 (StatSoft ® Inc. U.S.), and statistical signifi cance was defi ned 
as p ≤0.05.
Results
We analysed 168 cases (Kraków = 108, Miechów = 60), including 102 women 
(61%) and 66 men (39%). In the  analysed period in the  Infectious Diseases 
Department of the  University Hospital in Kraków there were 3185 hospitalised 
patients and in the  University Hospital as a  whole — 221,188. Th e  percentage of 
people hospitalised due to CDI in the  Infectious Diseases Department was 3.4%. 
In the  hospital in Miechów the  analysed patients had been treated in various 
departments, including 40 people from Infectious Diseases, 12 from Pulmonary 
Diseases, 3  Cardiology, and 3 Internal Diseases, 1 patient from Neurology and 1 — 
Paediatrics Department. In the analysed period in the hospital in Miechów there were 
10,318 hospitalisations, in the  Infectious Diseases Department 702, the percentage of 
patients treated for CDI was 0.6% in the Hospital and 5.7% in the Infectious Diseases 
Department itself.
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Th e median age of the  patients was 74 years for the  entire population (range 
8–93 years), 76 years in the case of women and 71 years for men. 130 persons (77%) 
experienced only 1 episode, whereas 38 people (23%) had more than 1 episode of 
infection. Th e mean number of CDI episodes was 1.33 for the whole analysed group, 
whereas for the people experiencing recurrences — 2.5. Th e patient with the  largest 
number of recurrence episodes had 9 of them altogether. Th e distribution of age, sex 
in the analysed group is presented in Tables 1 and 2.
Table 1. Th e age distribution of CDI in the analysed group.
Age n Median (range) years
Total 168 74 (8–93)
Women 102 76 (25–93)
Men 66 71 (8–92)
CDI — Clostridium diffi  cile infection.
Table 2. Distribution of the study group based on age and sex.
Total Women Men
<65 y/o 46 (27%) 25 (54%) 21 (46%)
>65 y/o 122 (73%) 77 (63%) 45 (37%)
y/o — years old.
In the  study group 113 people (67%) had been hospitalised in the  preceding 
3  months, in 2 cases we were unable to ascertain the  duration. Forty four people 
declared no previous hospitalisation, 5 had been under nursing home, in 6 cases there 
is no information on previous hospital stays. Th e average length of the hospital stay 
during CDI episode was (median) 11 days (Q25–Q75: 8–17 days), an average length 
of hospital stay before analysed episode of CDI was very similar (median = 11 days, 
 Q25–Q75: 8–16 days).
Ninety nine people (59%) were treated with antibiotics within 3 months before 
the  episode of infection, 39 (23%) defi nitely did not have such therapy, whilst in 
the  case of 30 people (18%) this cannot be determined on the  basis of the  patient 
documentation. Among the 99 people having received antibiotic treatment — 83 have 
given the  name of the  medication, whereas in 16 cases the  patients were certain of 
having taken antibiotics but could not remember the name(s). Th e type of antibiotics 
therapy used before the fi rst episode of CDI is presented in Table 3.
The type of CDI treatment and average values of the  most significant blood 
parameters are presented in Tables 4 and 5. 
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Table 3. Antibiotics used before the episode of CDI. 
Antibiotic n (%)*
amoxicillin/clavulanic acid 29 (35%)
ciprofl oxacin 28 (34%)
cefuroxime 20 (24%)
ceft riaxone 14 (17%)
amikacin 4 (4.8%)
amoxicillin 3 (3.6%)
ceft azidime 3 (3.6%)
clindamycin 3 (3.6%)
vancomycin IV 3 (3.6%)
cefalexin 2 (2.4%)
cefotaxime 2 (2.4%)
doxycycline 2 (2.4%)
imipenem/cilastatin 2 (2.4%)
clarithromycin 2 (2.4%)
metronidazole 2 (2.4%)
norfl oxacin 2 (2.4%)
sulfamethoxazole/trimethoprim 2 (2.4%)
furazidin 1 (1.2%)
gentamicin 1 (1.2%)
linezolid 1 (1.2%)
meropenem 1 (1.2%)
CDI — Clostridium diffi  cile infection
*  Th e  percentage was calculated in relation to where the  antibiotic used was 
known (n = 83). Some patients have used more than one antibiotic, therefore 
the percentage sum does not equal 100%.
Table 4. Values of analysed blood parameters.
Parameter
Study group CDI patients who died
n median Q25–Q75 range n median Q25–Q75 range
WBC × (103/ul) 165 11  7–16 3.1–46.8 18 18.5 11.4–26.6 6.5–46.8
CRP (mg/l) 160 60 16–108 0.2–333 18 116 54–146 19–333
Creatinine (μmol/l) 166 80 62–122 42–783 18 168 115–274 61–404
CDI — Clostridium diffi  cile infection; CRP — C-reactive protein; Q25 — lower quartile; Q75 — upper quartile; 
WBC — white blood cells
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Table 5. Th e frequency of the therapy used in the treatment of CDI.
Type of antibiotic therapy n
metronidazole P.O. 90 (54%)
vancomycin P.O. 45 (27%)
vancomycin P.O. + metronidazole IV 19 (11%)
P.O. metronidazole poorly tolerated or deemed ineff ective, subsequently switched to P.O. 
vancomycin
12 (7%)
no treatment 2 (1%)
CDI — Clostridium diffi  cile infection; IV — intravenously; P.O. — orally
Th ere were 18 deaths in the  study group (10.7%). Th ose patients who died were 
statistically signifi cantly older (p = 0.049), exhibited higher values of white blood cells 
— WBC (p <0.001), CRP (p = 0.004), creatinine (p <0.001) in comparison to those 
who survived.
The frequency of the  comorbidities which are known risk factors for CDI 
development are presented in Table 6. In 53 people (32%), found comorbidities may 
have been a  predisposing factor to CDI development. Among the  15 people with 
gastrointestinal disorders, in 9 cases it was diverticulosis. Six out of 19 people with 
malignancies had undergone chemo- and/or radiotherapy. Eight out of 16 people with 
chronic kidney failure required dialysis.
Table 6. Th e incidence of comorbidities or therapy other than antibiotics that are risk factors for CDI.
Predisposing factor n (%)*
Malignancy 19 (11.3%)
Chronic kidney disease 16 (9.5%)
Gastrointestinal disorders 15 (8.9%)
Immunosuppressive therapy # 9 (5.4%)
Autoimmune disease 4 (2.4%)
HIV infection 1 (0.6%)
Cirrhosis 1 (0.6%)
CDI — Clostridium diffi  cile infection
*  the percentage was calculated in relation to the whole analysed group 
(n = 168).
In some patients, multiple risk factors were present, therefore the  per-
centage sum does not equal 100%.
# malignancy treatment not included.
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Th e next question asked was how many patients presented with no known risk 
factors of CDI. Having excluded those not previously hospitalised, left  were 44 (26%) 
persons who had not been hospitalised during last 3 months, nor had they been 
in nursing homes. Among them, there were 26 persons who had used antibiotics 
previously, 9 people had defi nitely not used them and in case of 9 there was no 
certain data. Looking for the  risk factors in a  remaining group of 9 persons with 
no hospitalization and no certain antibiotic we found that 6 of them were above 
age of 65 years. Finally, 3 people aged 54–55 were left ; one of them suff ered from 
a  chronic autoimmune disease (scleroderma), another was additionally diagnosed 
with salmonellosis. Ultimately, in the  group of 168 people, there was only 1 person 
with no known CDI risk factor found. 
Discussion
Th e risk factors for the  development of CDI are those which disrupt the  normal 
intestinal fl ora, mainly therapy with broad-spectrum antibiotics, host-related factors 
(of which age is the  most signifi cant), as well as environmental factors, such as 
the exposure to C. diffi  cile usually associated with hospital stay with the source being 
the hospital environment [10–12]. Gastrointestinal infections also lead to destruction 
or impairment of gut microbiota, possibly facilitating CDI even in a  younger 
population, as demonstrated in our 2018 study [13]. Practically the  majority of 
antibiotics may lead to development of CDI, yet most oft en the  infection is caused 
by clindamycin, third-generation cephalosporins, fl uoroquinoles and broad-spectrum 
penicillins [12]. Th e  risk in age >65 years old is 5 to 10-fold higher than in people 
aged  <65 years [10, 14, 15]. Hospitalisation is an important risk factor of CDI. 
According to epidemiological data, the risk of C. diffi  cile colonisation in hospitalised 
patients is approximately 3–40%, average 10–15%. C. diffi  cile is the  most common 
cause of nosocomial gastrointestinal infection and nosocomial diarrhoea (10–30% 
of cases). Notably, only 25–30% of people colonised with this pathogen during 
hospitalisation will develop diarrhoea. Th e  incidence of colonization is related to 
the  duration of hospitalisation [16, 17]. Johnson et al. observed the  colonisation 
in approximately 1% of patients hospitalised for up to 1 week, while it increased 
to approximately 50% in patients hospitalised for over 4 weeks [18]. Sources of 
the  pathogen are the  people infected with C. diffi  cile and the  hospital environment. 
Th e  spores remain in the  environment for several months and can be found in 
the  vicinity of toilets, but also on hospital furniture, phones and medical equipment 
like thermometers and stethoscopes. Th e role of medical personnel in the transmission 
of the  pathogen from the  hospital environment to patients should be emphasized. 
Johnson et al. demonstrated that consistent use of latex gloves was associated with 
reduction of risk of CDI [19].
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To sum up the  above-named factors’ triad, i.e. therapy with antibiotics, old age 
and hospital stay are the main causes for the development of CDI. An elderly person 
who is hospitalised for pneumonia is a  model example for the  risks factors of CDI 
development. In our analysis, people above 65 years of age were the  majority and 
amounted to 73%. Th e percentage was higher for women than for men, which probably 
is due to a longer lifespan of women. Nevertheless, approximately 25% of the infected 
people were below 65 years of age, whilst the youngest was 8 years old. Most probably 
an overall increase of the frequency of infections facilitates the spread among younger 
age groups. In our study we tried to determine the  signifi cance of the  presence of 
one of the  3 risk factors, i.e. elderly age, antibiotic therapy and hospital treatment. 
Th e  most frequently present risk factor was the  age >65 (73%), then hospital stay 
(67%), and treatment with antibiotics (59%). However, the data concerning antibiotics 
could be underestimated as with as many as 18% persons it was not possible to 
determine whether there had been any antibiotics used recently. Having analysed 
the risk factors of CDI, it bears emphasising that only 1 person with no known CDI 
risk factors was found. Th is allows to conclude that the  risk of development of CDI 
in a group with no risk factors is minimal. Th e role of protein pump inhibitors (PPI) 
remains controversial. Some correlation was initially reported, but subsequent analysis 
adjusted for other comorbidities did not confi rm this hypothesis; especially since it 
has been demonstrated that C. diffi  cile spores are resistant to the acidic environment 
of the  stomach. With that in mind, the  eff ect of PPI on risk of CDI has not been 
assessed in our study [20, 21]. Th e analysis of the antibiotics used before the infection 
with C. diffi  cile shows that broad-spectrum penicillins and fl uoroquinoles are most 
likely to facilitate the development of infection. In the study group only 3.6% people 
had been treated with clindamycin, which has a  general opinion of the  antibiotic 
responsible for the development of CDI. Th e explanation of this phenomenon is quite 
diffi  cult. On one hand, this might be explained with a  larger awareness of the risk of 
CDI aft er treatment with clindamycin and thus the  limitation of its use, on the other 
— with an exaggerated signifi cance of clindamycin in CDI development.
Th e clinical picture of CDI is diverse and ranges from asymptomatic carrier status, 
through various degrees of diarrhoea, to the most severe, life threatening cases. CDI 
infection may aff ect every part of the  large intestine, but usually it is located in its 
distal portion [12]. Th e  diarrhoea, which is usually watery and sometimes intense, 
may be accompanied by abdominal pain, fever, nausea, vomiting, fatigue and anorexia. 
Occult blood is frequently present in faeces, but overt bleeding is usually absent. In 
the most severe form of the disease, the signs and symptoms are similar to those of 
colitis, but they are more intense and may lead to signifi cant dehydration, oedema 
and shock. Th e most serious complications are: toxic megacolon, perforation of large 
intestine, paralytic ileus, renal insuffi  ciency and sepsis. Th e most signifi cant adverse 
prognostic factors in CDI are age, high WBC counts, CRP and creatinine levels. 
 Analysis of risk factors and outcomes of Clostridium diffi  cile infection 113
Th e  high WBC count and CRP level refl ect the  infl ammation of the  colon, while 
elevated creatinine levels correlate with dehydration caused by diarrhoea [12, 22, 23]. 
Our study confi rms increased values of WBC, CRP, creatinine. It is worth pointing to 
signifi cantly larger values of these parameters among those in whose case the disease 
led to death in comparison to the  whole group (CRP 116 vs 60 mg/l, respectively), 
(creatinine 168 vs 80 μmol/l, respectively) and, in particular, very high leukocyte count 
(18 vs 11.5 × 103/ul, respectively). In clinical practice this is always a  factor which 
worsens the  prognoses and in such situations, a  combined therapy of intravenous 
metronidazole and oral vancomycin should always be considered. Our study does not 
include one parameter important in CDI- blood albumin levels. Th is particular test 
was, unfortunately, performed very rarely in the analysed patients.
In 2018 new guidelines for CDI treatment were published. In nonsevere cases 
the  fi rst-line treatment is oral vancomycin 125 mg every 6 hours for 10 days or 
fi daxomicin 200 mg orally twice a  day for 10 days. Metronidazole 500 mg orally 
three times a  day for 10 days can be administrated if above agents are unavailable. 
In severe cases the  drug of choice is the  oral vancomycin 125 mg every 6 hours 
or fi daxomicin 200 mg orally twice a  day (10 days) and in complicated cases it is 
recommended to combine oral vancomycin (500 mg every 6 hours) with intravenous 
metronidazole 500 mg every 8 hours (10–14 days). Moreover, in case of ileus, rectal 
route of administration of vancomycin can be also used, in dose 500 mg diluted in 
100 ml of the 0.9% NaCl every 6 hours [3, 20, 24, 25]. Intravenous use of vancomycin 
is not recommended because it is associated with insufficient concentrations of 
the  drug in the  intestine. Gastrointestinal absorption of vancomycin is minimal 
and its oral administration allows to achieve therapeutic concentrations within 
the  intestine, while avoiding the side eff ects observed with parenteral administration. 
Th e  time of resolution of diarrhoea may be shorter with vancomycin compared to 
metronidazole [26, 27].
In the  study group oral metronidazole was the  most frequently used drug 
(54%). Bad tolerance and/or ineffectiveness of metronidazole was present in 
a  group of 12 people (7%). Vancomycin is also the  drug of choice in people 
with significant liver damage. We analyzed patients with CDI treated before 
updating of guidelines. Nevertheless, having evaluated the  percentage of the  P.O. 
metronidazole + IV vancomycin therapy and the percentage of deaths, it seems that 
in the analysed group, the use of the strongest therapy was too low. It is important to 
underline that from 2018 vancomycin and fi daxomicin are the  cornerstone of CDI 
treatment [25].
Mortality in CDI is highest in elderly patients with multiple comorbidities, in 
whom it may reach 25% [10]. In our study there were 18 deaths in the  analysed 
group (11%). 15 patients died during their fi rst episode of infection, which confi rms 
the observation that among many people with recurrences, the  largest intensifi cation 
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of symptoms occurs during the fi rst episode [28]. Each consecutive recurrence is less 
dynamic, and, fi nally no recurrences take place. Asymptomatic carriers of C. diffi  ccile 
have a high titre of antibodies against A and B toxin [29]. It is believed that some of 
the  recurrences can be attributed to an ineffi  cient creation of protective antibodies, 
and each episode of the  disease increases their number until the  level protection 
against the  disease is reached. A  recurrence of the  symptoms of infection usually 
takes place about 1 week aft er the  end of the  causal treatment. Th e  patients who 
experienced one recurrence, have a larger risk of further recurrences. CDI recurrence 
in one half of the  cases is caused by the  same bacterial strain and in about half of 
the cases — by a diff erent strain of C. diffi  cile [22, 30]. Also in our group, the average 
time of recurrence was about one week. With some of our patients, the  recurrences 
took place with very high regularity.
Conclusions
Although any progress in medicine leads to narrowing down the  areas of 
specialisation, it must be stressed that the  problem of CDI concerns all hospital 
wards and specialisations. Infection caused by C. diffi  cile is an increasing problem 
during hospitalisation, particular among elderly patients, irrespectively of the  type 
of hospital ward. It is paramount to revisit the  handling of a  CDI patient not only 
among doctors of diff erent specialties, but the  nursing and support staff , extending 
basic CDI-related care to the  patients’ families with an emphasis on elderly people. 
A general use of cephalosporins, and penicillin-type antibiotics is the cause of a larger 
number of infections with C. diffi  cile. Vast majority of patients have had at least one 
typical risk factor of CDI development. Based on our observations, blood albumin 
levels were not tested frequently enough; this test should be performed routinely, as 
it is important for formulating a prognosis of risk of death, selecting medication and 
supplementation. 
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